Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Medinotec (MDNC) EBITDA Margin (2022 - 2025)

Medinotec's EBITDA Margin history spans 4 years, with the latest figure at 26.13% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1458.0% year-over-year to 26.13%; the TTM value through Nov 2025 reached 22.44%, up 1290.0%, while the annual FY2025 figure was 23.08%, 3083.0% up from the prior year.
  • EBITDA Margin reached 26.13% in Q4 2025 per MDNC's latest filing, up from 11.11% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 40.99% in Q1 2025 to a low of 108.23% in Q3 2022.
  • Average EBITDA Margin over 4 years is 5.18%, with a median of 4.34% recorded in 2025.
  • The largest YoY upside for EBITDA Margin was 9232bps in 2023 against a maximum downside of -1198bps in 2023.
  • A 4-year view of EBITDA Margin shows it stood at 12.58% in 2022, then tumbled by -95bps to 24.56% in 2023, then soared by 147bps to 11.54% in 2024, then surged by 126bps to 26.13% in 2025.
  • Per Business Quant, the three most recent readings for MDNC's EBITDA Margin are 26.13% (Q4 2025), 11.11% (Q3 2025), and 4.59% (Q2 2025).